^Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (2001). „Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics. 296 (2): 338—44. PMID11160615.
^Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE (1996). „9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore”. Journal of Medicinal Chemistry. 39 (2): 549—55. PMID8558526. doi:10.1021/jm950707.
^Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G (2002). „(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist”. Journal of Medicinal Chemistry. 45 (17): 3660—8. PMID12166939. doi:10.1021/jm0101545.
^Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB (2004). „Synthesis and SAR exploration of dinapsoline analogues”. Bioorg. Med. Chem. 12 (4): 715—34. PMID14759732. doi:10.1016/j.bmc.2003.11.015.
^Gleason SD, Witkin JM (2006). „Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine”. Psychopharmacology (Berl.). 186 (1): 25—31. PMID16575553. doi:10.1007/s00213-006-0342-2.
